These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9439448)

  • 1. IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide.
    Griesmacher A; Weigel G; Seebacher G; Müller MM
    Clin Chem; 1997 Dec; 43(12):2312-7. PubMed ID: 9439448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of mycophenolic acid alone and in combination with its metabolite mycophenolic acid glucuronide on rat embryos in vitro.
    Schmidt F; Eckardt K; Shakibaei M; Glander P; Stahlmann R
    Arch Toxicol; 2013 Feb; 87(2):361-70. PubMed ID: 22914985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of mycophenolate acyl-glucuronide on human recombinant type 2 inosine monophosphate dehydrogenase.
    Gensburger O; Picard N; Marquet P
    Clin Chem; 2009 May; 55(5):986-93. PubMed ID: 19299544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics.
    Nowak I; Shaw LM
    Clin Chem; 1995 Jul; 41(7):1011-7. PubMed ID: 7600680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity.
    Nowak I; Shaw LM
    Ther Drug Monit; 1997 Jun; 19(3):358-60. PubMed ID: 9200779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inosine monophosphate dehydrogenase activity depends on plasma concentrations of mycophenolic acid and its glucuronides in kidney transplant recipients.
    Mino Y; Naito T; Otsuka A; Ozono S; Kagawa Y; Kawakami J
    Clin Chim Acta; 2009 Nov; 409(1-2):56-61. PubMed ID: 19723513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of mycophenolate mofetil.
    Ransom JT
    Ther Drug Monit; 1995 Dec; 17(6):681-4. PubMed ID: 8588241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients.
    van Hest RM; van Gelder T; Vulto AG; Shaw LM; Mathot RA
    Clin Pharmacokinet; 2009; 48(7):463-76. PubMed ID: 19691368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolic acid monitoring in HTX patients: a preliminary report.
    Müller MM; Vogl M; Griesmacher A
    Therapie; 1997; 52(4):341-4. PubMed ID: 9437889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3.
    Uwai Y; Motohashi H; Tsuji Y; Ueo H; Katsura T; Inui K
    Biochem Pharmacol; 2007 Jun; 74(1):161-8. PubMed ID: 17462604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy.
    Vethe NT; Bergan S
    Ther Drug Monit; 2006 Oct; 28(5):608-13. PubMed ID: 17038874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil.
    Shipkova M; Armstrong VW; Wieland E; Niedmann PD; Schütz E; Brenner-Weiss G; Voihsel M; Braun F; Oellerich M
    Br J Pharmacol; 1999 Mar; 126(5):1075-82. PubMed ID: 10204993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis.
    Quéméneur L; Flacher M; Gerland LM; Ffrench M; Revillard JP; Bonnefoy-Berard N
    J Immunol; 2002 Sep; 169(5):2747-55. PubMed ID: 12193749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis.
    Sam WJ; Joy MS
    Ther Drug Monit; 2010 Oct; 32(5):594-605. PubMed ID: 20736896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPLC determination of mycophenolic acid and mycophenolic acid glucuronide in human plasma with hybrid material.
    Bolon M; Jeanpierre L; El Barkil M; Chelbi K; Sauviat M; Boulieu R
    J Pharm Biomed Anal; 2004 Nov; 36(3):649-51. PubMed ID: 15522544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of IMPDH1 is regulated in response to mycophenolate concentration.
    Bremer S; Vethe NT; Rootwelt H; Bergan S
    Int Immunopharmacol; 2009 Feb; 9(2):173-80. PubMed ID: 19010451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic influences on mycophenolate therapy.
    Barraclough KA; Lee KJ; Staatz CE
    Pharmacogenomics; 2010 Mar; 11(3):369-90. PubMed ID: 20235793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.
    Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K
    Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.